Tag: GLP-1 receptor agonists

Adults with obesity who achieved major weight loss over one year showed increased subcortical gray matter volume and improved metabolic ...

A retrospective study of over 46,000 propensity-matched women with diabetes and hypertension found GLP-1 receptor agonist use was associated with ...

A new review proposes the MMCK syndrome, an operational extension of the CKM framework that integrates MASLD liver fibrosis scoring ...

A new review finds that combining SGLT2 inhibitors with GLP-1 receptor agonists in heart failure is mechanistically plausible and generally ...

A published case report describes a woman with type 2 diabetes and recurrent hypertriglyceridemia-mediated pancreatitis whose triglycerides, blood sugar and ...

Liraglutide reduced proteinuria and kidney injury in lupus-prone mice through anti-inflammatory, antioxidant, and ferroptosis-related mechanisms, with cAMP signaling implicated.

A cross-sectional study of 7,697 adults with type 2 diabetes found GLP-1 receptor agonist use was associated with lower TFQI ...

A small Mayo Clinic exploratory study suggests AI-enabled chest x-ray staging can detect subclinical diastolic dysfunction in obesity and diabetes ...

A retrospective matched study of 16,792 patients with type 2 diabetes found GLP-1 receptor agonist use before necrotizing soft tissue ...

A subject-level analysis of 91 placebo-controlled trials covering nearly 108,000 participants found no increased risk of suicidal ideation or behavior ...

A new commentary argues that GLP-1 receptor agonists' heart failure hospitalization benefit may not apply across all heart failure phenotypes.

A new review in Cardiovascular Diabetology describes how FDA-approved oral GLP-1 receptor agonists such as semaglutide and orforglipron are expanding ...

A new review maps how oxidative stress and inflammation drive diabetic nephropathy and highlights biomarkers and drugs for earlier detection ...

A GeroScience commentary argues that veterinary conditional approval frameworks and existing mortality-benefiting drugs could guide human lifespan therapeutics development.

A new narrative review argues that GLP-1 receptor agonists should be repositioned as foundational cardio-renal-metabolic protectors, with trial evidence extending ...

An exploratory mouse study found that 28 days of semaglutide exposure significantly increased the osteoblast-covered bone surface without detectable changes ...

A meta-analysis of five phase 3 trials found that incretin-based therapies lowered DXA-measured lean body mass versus comparators, though certainty ...

A new narrative review argues that chronic inflammation, gut microbiota dysbiosis, and mitochondrial dysfunction are reshaping type 2 diabetes care ...

Current evidence shows that while GLP-1 receptor agonists increase retained gastric contents, they have not been linked to a corresponding ...

A systematic review of nine randomized studies finds exploratory biomarker and neuroimaging signals for GLP-1 receptor agonists and SGLT-2 inhibitors ...